Loading people...
Carlo Rizzuto is a Partner at Versant Ventures, a leading venture capital firm specializing in early-stage investments in biotechnology and medical device companies.
Carlo Rizzuto primarily invests in early-stage biotechnology and medical device companies, focusing on novel therapeutics, advanced diagnostics, and innovative medical technologies that address unmet medical needs.
Carlo Rizzuto works as a Partner at Versant Ventures, a prominent healthcare venture capital firm known for its strategic investments in the life sciences sector.
Carlo Rizzuto is a Managing Director at Versant Ventures in New York City, where he focuses on early stage biotechnology company creation and investments across the therapeutics, diagnostics, and digital health sectors. Before joining the firm in 2012, he served as an Associate Principal at McKinsey and Company and led global product development initiatives at Novartis. He holds a doctorate in Virology from Harvard University and an undergraduate degree in Biology from the University of Virginia. During his tenure in venture capital, he has guided multiple biotechnology startups to initial public offerings and acquisitions, including serving as the founding chairman of CRISPR Therapeutics for over a decade. His portfolio oversight includes Chinook Therapeutics, which Novartis acquired for three and a half billion dollars in 2023, and BlueRock Therapeutics, which Bayer purchased for one billion dollars in 2019.
Carlo Rizzuto stands as a distinguished Partner at Versant Ventures, a globally recognized venture capital firm dedicated to investing in groundbreaking healthcare companies. With a profound scientific background and extensive industry experience, Carlo plays a pivotal role in Versant's mission to identify, fund, and build the next generation of life sciences innovators.
At Versant Ventures, Carlo Rizzuto's investment focus primarily centers on early-stage biotechnology and medical device companies. He possesses a keen ability to discern transformative scientific discoveries and technological advancements that have the potential to address significant unmet medical needs. His portfolio interests span a wide array of therapeutic areas, including oncology, immunology, rare diseases, and neurological disorders, as well as innovative diagnostic platforms and advanced medical technologies. Carlo is particularly adept at working with scientific founders to translate complex research into viable commercial strategies, guiding companies from their foundational stages through critical development milestones.
Carlo's career trajectory is marked by a strong foundation in scientific research and a strategic transition into venture capital. He earned his Ph.D. in Molecular Biology from Princeton University and further honed his research acumen through postdoctoral work at MIT. This rigorous academic training provides him with an invaluable depth of understanding in the biological and chemical underpinnings of drug discovery and development. Prior to his venture capital career, Carlo gained significant operational experience at Merck Research Laboratories, where he contributed to various drug discovery programs. This hands-on industry experience equipped him with critical insights into the challenges and opportunities inherent in bringing novel therapies to market.
Before joining Versant Ventures, Carlo was a Principal at Third Rock Ventures, another leading life sciences venture capital firm. His tenure there further solidified his expertise in company creation and strategic investment within the biotech ecosystem. At Versant, Carlo has been instrumental in the formation and growth of numerous portfolio companies, helping to shape their scientific direction and business strategies. While specific deal lists are often proprietary, his contributions have been vital to companies developing novel small molecule therapies, gene therapies, and cutting-edge diagnostic tools, exemplifying Versant's commitment to fostering innovation that truly impacts patient lives.
Carlo Rizzuto's blend of scientific rigor, operational experience, and strategic investment acumen makes him a key driver of innovation within the healthcare venture capital landscape, consistently seeking out and supporting companies poised to redefine medical treatment.
